4basebio PLC, an innovation-driven biotechnology company, has announced the exercise of EMI options by an employee over 9,000 ordinary shares in the company. The exercise price of the shares is £3.65 per share, resulting in total proceeds of £32,850. The New Ordinary Shares are expected to be admitted to trading on AIM, with the admission becoming effective at 8.00 a.m. on or around 9 February 2024. These shares will be fully paid and will rank equally with existing ordinary shares for dividends and other distributions.

Following the Admission, the total number of ordinary shares in issue will be 12,805,208, with no ordinary shares held in treasury. This figure will be used by shareholders to determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

The announcement contains inside information for the purposes of EU Regulation 596/2014. For further enquiries, interested parties can contact 4basebio PLC or its financial advisers.